Immune Cells: Growing microglia in the lab
Transplanting microglia derived from human stem cells into mice reveals new possibilities for treating neurodegenerative eye diseases.
- FireCyte Therapeutics, Inc, United States
- Schepens Eye Research Institute of Mass. Eye and Ear, Department of Ophthalmology, Harvard Medical School, United States
As the global population gets older, age-related diseases are becoming more prevalent, with many linked to dysfunctional immune responses. In the central nervous system, microglia are resident immune cells that maintain homeostasis, respond to injury and regulate inflammation. However, these cells can become dysregulated over time, and the resulting inflammation has been implicated in age-related neurodegenerative diseases, including Alzheimer’s disease (Cai et al., 2022) and Parkinson’s disease (Tansey et al., 2022), as well as diseases that affect the retina, such as glaucoma (Wei et al., 2019; Pan et al., 2023). However, despite extensive research into methods for shifting microglia from a dysfunctional state back into a state that can protect the nervous system, there are currently no drugs that have been approved to do this.
Microglia derived from induced pluripotent stem cells (iPSCs) – adult cells that have been reprogrammed to have the same properties as embryonic stem cells – offer a powerful way to study human microglia in healthy and diseased states. When sourced directly from patients, these cells offer a renewable, patient-specific model with the potential to be used therapeutically to replace dysfunctional microglia with healthier versions without the risk of immune rejection. Now, in eLife, Wai T Wong (Tiresias Bio), Wei Li (National Eye Institute) and colleagues – including Wenxin Ma as first author – report the results of initial efforts to develop iPSC-derived microglia that can be used to treat retinal diseases (Ma et al., 2024).
First, Ma et al. optimized previously reported methods for the production of human microglial cells from iPSCs. This enabled them to continuously produce microglia at a purity (often greater than 95%) and a scale that could support both research and the commercialization of their approach. Testing the method in five distinct stem cell lines showed that it was broadly applicable, increasing the likelihood that it could be used to generate microglia from individual patients.
Gene expression profiles from the resulting microglia closely resembled those of native microglia and were clearly distinct from the progenitor iPSCs. Challenging the iPSC-derived microglia with bacteria revealed that they displayed two hallmark functional activities of native microglia: (i) they secreted proteins associated with inflammatory responses when exposed to bacterial toxins; (ii) they engulfed particles coated with bacteria.
Next, the team optimized a procedure for replacing dysfunctional microglia in the retina with healthy microglia derived from iPSCs. In mice, native microglia in the retina were depleted by inhibiting a receptor required for their survival, and fluorescent human iPSC-derived microglia were then injected into the subretinal space. Over the course of 3–6 months, the human microglial cells successfully repopulated the retina and integrated across all retinal layers (Figure 1). Some native mouse microglia were also present in the retina, but at greatly reduced numbers. The human microglia assumed characteristic shapes that indicated they had taken on a protective and supportive functional state.
Figure 1
A method for producing human iPSC-derived microglia and transplanting them into mice.
During the production stage (top left), embryoid bodies derived from human iPSCs (induced pluripotent stem cells; pink) develop into myeloid precursors, which then differentiate into microglia (green cells) after exposure to a cocktail of cytokines (IL-34, CSF1, TGFβ, and Cx3cl1). The microglia derived from the iPSCs express typical microglia markers (such as Cx3cr1, P2ry12, CD11b, and CD68). During the confirmation stage (top right), the properties of the microglia are validated through a combination of gene profiling, comparative Gene Pathway Analysis, phagocytosis assays (which probe the ability of the microglia to engulf particles coated with bacterial proteins), and xenotransplantation (which involves transplanting the microglia into the subretinal space of adult mice; bottom right). Xenotransplantation is followed by the repopulation stage (bottom left), in which the microglia derived from the iPSCs become integrated and distributed across the different retinal layers in a pattern consistent with endogenous microglia (red cell). GCL: ganglion cell layer; INL: inner nuclear layer; ONL: outer nuclear layer; RPE: retinal pigment epithelium.
Lastly, Ma et al. determined whether the transplanted human microglia could respond to retinal damage. Killing photoreceptors (the cells that detect light) by administering high doses of the chemical sodium iodate (Kannan and Hinton, 2014), caused the human microglia to transiently proliferate and migrate into the layer of the retina containing the photoreceptors. Moreover, the human microglia began to consume the cellular debris created by the dying photoreceptors. These responses mirror the actions of native microglia and reflect the critical ability of the iPSC-derived microglia to protect the remaining healthy photoreceptor cells.
With this innovative approach, a biopsy of skin cells from a patient with glaucoma could be transformed into the very cells that might halt or prevent blindness. Even more intriguing, the mouse model developed by Ma et al. to allow transplantation of iPSC-derived human microglia represents a valuable platform for discovering even more therapies for retinal diseases. Taken together, the findings of Ma et al. represent a significant step forward in developing new therapeutic approaches for treating age-related central nervous system disorders where microglial dysfunction plays a central role.
References
-
Sodium iodate induced retinal degeneration: new insights from an old modelNeural Regeneration Research 9:2044–2045.https://doi.org/10.4103/1673-5374.147927
-
Inflammation and immune dysfunction in Parkinson diseaseNature Reviews Immunology 22:657–673.https://doi.org/10.1038/s41577-022-00684-6
-
Neuroinflammation and microglia in glaucoma: time for a paradigm shiftJournal of Neuroscience Research 97:70–76.https://doi.org/10.1002/jnr.24256
Article and author information
Author details
Jonathan M Levenson
Publication history
Copyright
© 2024, Levenson et al.
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Immune Cells: Growing microglia in the lab
eLife 13:e103535.
https://doi.org/10.7554/eLife.103535
Further reading
-
- Cell Biology
- Stem Cells and Regenerative Medicine
Our understanding of the transitions of human embryonic stem cells (hESCs) between distinct stages of pluripotency relies predominantly on regulation by transcriptional and epigenetic programs with limited insight on the role of established morphological changes. We report remodeling of the actin cytoskeleton of hESCs as they transition from primed to naïve pluripotency which includes assembly of a ring of contractile actin filaments encapsulating colonies of naïve hESCs. Activity of the Arp2/3 complex is required for formation of the actin ring, to establish uniform cell mechanics within naïve colonies, to promote nuclear translocation of the Hippo pathway effectors YAP and TAZ, and for effective transition to naïve pluripotency. RNA-sequencing analysis confirms that Arp2/3 complex activity regulates Hippo signaling in hESCs, and impaired naïve pluripotency with inhibited Arp2/3 complex activity is rescued by expressing a constitutively active, nuclear-localized YAP-S127A. Moreover, expression of YAP-S127A partially restores the actin filament fence with Arp2/3 complex inhibition, suggesting that actin filament remodeling is both upstream and downstream of YAP activity. These new findings on the cell biology of hESCs reveal a mechanism for cytoskeletal dynamics coordinating cell mechanics to regulate gene expression and facilitate transitions between pluripotency states.
-
- Cell Biology
- Stem Cells and Regenerative Medicine
New evidence sheds light on actin regulation of pluripotency in human embryonic stem cells.
